JOINN(06127)

Search documents
昭衍新药(06127) - 2022 Q3 - 季度财报
2022-10-28 11:28
Financial Performance - The company's operating revenue for the third quarter was RMB 499,511,815.43, representing a year-on-year increase of 55.01%[4] - Net profit attributable to shareholders for the third quarter was RMB 260,913,556.78, showing a significant year-on-year growth of 176.77%[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses reached RMB 260,340,236.28, with a year-on-year increase of 195.97%[4] - The basic earnings per share for the third quarter was RMB 0.49, an increase of 88.46% compared to the same period last year[5] - The diluted earnings per share for the third quarter was RMB 0.49, with an increase of 88.46% compared to the same period last year[5] - The company reported a net profit attributable to shareholders for the year-to-date of 154.85%, driven by business growth and increased financial income[11] - Diluted earnings per share for the year-to-date increased by 76.12%, due to business growth and increased financial income[12] - Total revenue for the first three quarters of 2022 reached ¥1,276,392,981.45, a significant increase from ¥856,804,399.15 in the same period of 2021, representing a growth of approximately 49%[22] - Net profit attributable to shareholders of the parent company for the first three quarters of 2022 was ¥632,033,151.04, up from ¥248,006,161.31 in 2021, reflecting a growth of approximately 154%[24] - Basic earnings per share for the first three quarters of 2022 were ¥1.18, compared to ¥0.68 in the same period of 2021, marking an increase of about 74%[25] Cash Flow and Assets - The net cash flow from operating activities for the year-to-date was RMB 778,288,380.46, representing a year-on-year increase of 67.93%[4] - Cash flow from operating activities for the year-to-date increased by 67.93%, due to increased sales collections and interest income[11] - Cash inflow from operating activities in the first three quarters of 2022 was ¥2,085,281,684.08, compared to ¥1,422,490,961.55 in 2021, showing an increase of approximately 47%[28] - The total assets at the end of the reporting period amounted to RMB 10,079,078,937.04, reflecting an increase of 18.06% from the end of the previous year[5] - Current assets totaled approximately 5.72 billion RMB, slightly down from 5.81 billion RMB at the end of 2021, indicating a decrease of about 1.2%[18] - The company's cash and cash equivalents were reported at approximately 2.87 billion RMB, down from 4.15 billion RMB at the end of 2021, a decline of about 30.8%[17] - The total cash and cash equivalents at the end of the third quarter of 2022 were approximately 2.85 billion, down from 4.11 billion at the end of the same period in 2021[31] - The company reported a net increase in cash and cash equivalents of approximately -1.30 billion in the first three quarters of 2022, compared to an increase of 3.81 billion in the same period of 2021[31] Liabilities and Equity - The total liabilities increased to approximately 2.41 billion RMB from 1.39 billion RMB, representing a growth of about 73.5%[20] - The company's equity attributable to shareholders rose to approximately 7.66 billion RMB, compared to 7.14 billion RMB at the end of 2021, an increase of about 7.4%[20] Inventory and Investments - The company reported a significant increase in inventory, which rose to approximately 2.21 billion RMB from 700.59 million RMB, a growth of about 215.5%[18] - The long-term investments decreased slightly to approximately 23.66 million RMB from 25.29 million RMB, a decline of about 6.5%[18] - The company experienced a decrease in investment income from joint ventures and associates, reporting a loss of ¥1,632,476.09 in the first three quarters of 2022[23] Operational Highlights - The company has secured a strong order backlog of over 4.6 billion RMB, ensuring robust future revenue growth[16] - The company has implemented effective measures to ensure the smooth delivery of orders, which is expected to positively impact future performance[16] - The company is focusing on new product development and market expansion strategies to enhance its competitive position in the industry[16] Research and Development - Research and development expenses for the first three quarters of 2022 amounted to ¥50,053,890.87, up from ¥35,019,894.79 in 2021, indicating a growth of about 43%[22] Other Financial Metrics - The company reported a loss of RMB 4,880,000 from the valuation changes of trading financial assets during the year-to-date[6] - The company recognized government subsidies amounting to RMB 8,457,000 for the year-to-date, compared to RMB 2,361,000 in the same period last year[7] - The company recorded a net loss of -3,089,926.69 from fair value changes in financial assets and liabilities[10] - The company has not defined any non-recurring gains and losses as recurring gains and losses[10] - Other comprehensive income after tax for the first three quarters of 2022 was ¥35,188,864.58, compared to -¥1,441,837.91 in 2021, indicating a positive turnaround[24]
昭衍新药(06127) - 2022 - 中期财报
2022-09-23 09:12
Financial Performance - JOINN Laboratories reported a revenue of 83 million RMB for the first half of 2022, reflecting a significant growth compared to the previous period[1]. - Revenue for the six months ended June 30, 2022, was RMB 776,881 thousand, representing a 45.3% increase compared to RMB 534,556 thousand in 2021[27]. - Gross profit for the same period was RMB 377,942 thousand, up 40.7% from RMB 268,571 thousand in 2021[27]. - Net profit for the period reached RMB 370,384 thousand, a significant increase of 141.9% from RMB 153,093 thousand in 2021[27]. - Basic earnings per share increased by 125.6% to RMB 0.97 from RMB 0.43 in the previous year[27]. - Total comprehensive income for the period was RMB 388,471 thousand, compared to RMB 150,725 thousand, reflecting a growth of 157.5%[122]. - The company reported a net profit of RMB 371,120 thousand for the six months ended June 30, 2022, compared to RMB 153,735 thousand for the same period in 2021, representing a significant increase[128]. - Cash generated from operating activities for the six months ended June 30, 2022, was RMB 545,494 thousand, compared to RMB 202,465 thousand for the same period in 2021, reflecting improved operational efficiency[131]. Growth and Expansion - The company has expanded its user base, with a 25% increase in clients year-over-year, indicating strong demand for its services[1]. - JOINN Laboratories projects a revenue growth of 15% for the next fiscal year, driven by new product launches and market expansion strategies[1]. - JOINN Laboratories aims to enter the Southeast Asian market by the end of 2023, which is expected to increase its market share significantly[1]. - The company is exploring potential acquisitions to enhance its market position, targeting companies with complementary services[1]. - The company has established strategic partnerships with three major pharmaceutical companies to enhance its service offerings[1]. - The company plans to establish a drug safety evaluation center in Guangzhou and a GLP-compliant non-clinical research laboratory in Chongqing, with operations expected to start in 2023[57]. - The company aims to enhance its global footprint and service capabilities, leveraging the strategic acquisition of Biomere to expand its presence in the North American pharmaceutical market[57]. Research and Development - The company is investing heavily in R&D, with a budget allocation of 20 million RMB for the development of new technologies and products in the upcoming year[1]. - The company is committed to ensuring stable operations and sustainable development in the future[29]. - The company has optimized various drug evaluation models, including those for ophthalmic and otologic drugs, enhancing its technical capabilities[35]. - The company is actively participating in a national project for the research of a new DNA vaccine platform, which received approval in the first half of 2022[35]. - The company has created over 30 disease animal models for preclinical drug efficacy evaluation, with plans to expand production capacity[38]. Operational Efficiency - The company reported a 30% increase in operational efficiency due to the implementation of new technologies in its laboratories[1]. - The company plans to integrate industry resources and deploy new business capabilities and service models to enhance operational efficiency[29]. - The company has established a wholly-owned subsidiary, Beijing Zhaoyan Drug Testing Research Co., Ltd., to enhance its cell testing business and support innovative drug development[37]. Financial Position - Total assets as of June 30, 2022, were RMB 10,646,728 thousand, reflecting a 24.7% increase from RMB 8,537,077 thousand at the end of 2021[28]. - Total liabilities increased by 132.7% to RMB 3,240,946 thousand from RMB 1,392,641 thousand in 2021[28]. - The company maintained a stable capital structure with a debt-to-equity ratio of 0.1% as of June 30, 2022, unchanged from December 31, 2021[52]. - As of June 30, 2022, cash and cash equivalents were RMB 3,801.0 million, a decrease of 8.5% from RMB 4,154.1 million at the end of 2021[51]. Employee and Shareholder Information - Employee costs totaled approximately RMB 303.0 million, up from RMB 212.7 million in the same period last year[56]. - The company has expanded its professional service team to over 2,600 members, an increase of nearly 500 from the end of 2021[31]. - The board does not recommend the payment of an interim dividend for the six months ended June 30, 2022[62]. - The company has granted a total of 3,785,000 stock options under various incentive plans, with an average exercise price of RMB 59.49 as of June 30, 2022[193]. Market Performance - The total order amount as of June 30, 2022, reached over RMB 4.1 billion, providing a solid foundation for future performance[39]. - The company signed orders exceeding RMB 2 billion in overseas markets, with a year-on-year growth of nearly 30%[41]. - The marketing efforts in the first half of 2022 resulted in over RMB 20 billion in signed orders, with domestic orders exceeding RMB 18 billion, a year-on-year increase of over 50%[40]. Sustainability and Corporate Governance - JOINN Laboratories is committed to sustainability, with plans to reduce its carbon footprint by 25% over the next five years[1]. - The company has adopted corporate governance principles and has complied with applicable code provisions during the six months ending June 30, 2022[110]. - There have been no significant litigation or arbitration cases from the listing date to June 30, 2022[112].
昭衍新药(06127) - 2022 Q1 - 季度财报
2022-04-28 14:31
Financial Performance - The company's operating revenue for Q1 2022 was RMB 270,975,486.87, representing a year-on-year increase of 34.82%[3] - Net profit attributable to shareholders for the same period was RMB 125,347,354.57, reflecting a growth of 34.27% year-on-year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 66.65% year-on-year, amounting to RMB 132,381,980.64[3] - Basic earnings per share for the quarter were RMB 0.33, up 17.86% year-on-year[3] - The company reported a significant increase in cash inflow from investment activities compared to the previous year, indicating a positive trend in investment returns[27] Cash Flow - The net cash flow from operating activities reached RMB 74,906,349.49, a significant increase of 117.23% compared to the previous year[3] - Cash inflow from investment activities totaled approximately $334.48 million, with a net cash inflow from investment activities of about $72.50 million[27] - The cash flow from operating activities generated a net amount of CNY 74,906,349.49 in Q1 2022, compared to CNY 34,482,082.76 in Q1 2021, indicating a growth of 117.5%[26] - The cash flow from investment activities showed a substantial improvement compared to the previous year's negative cash flow of approximately $66.69 million[27] - The company’s cash position remains strong, with a significant balance of cash and cash equivalents at the end of the reporting period[28] Assets and Liabilities - Total assets at the end of the reporting period were RMB 8,957,151,364.84, an increase of 4.92% from the end of the previous year[4] - Total current assets increased to CNY 6,186,990,976.77 as of March 31, 2022, compared to CNY 5,814,484,316.60 at the end of 2021, representing a growth of 6.4%[14] - Non-current assets totaled CNY 2,770,160,388.07 as of March 31, 2022, slightly up from CNY 2,722,592,794.80 at the end of 2021[15] - Total liabilities increased to CNY 1,685,280,811.53 as of March 31, 2022, compared to CNY 1,392,640,954.56 at the end of 2021, indicating a rise of 20.9%[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 31,729[10] - The top shareholder, Feng Yuxia, holds 89,702,855 shares, accounting for 23.51% of total shares[10] Business Growth - New orders signed exceeded 1 billion RMB, representing a year-on-year growth of over 65%[12] - The total amount of orders on hand reached over 3.6 billion RMB at the end of the reporting period[12] - Operating revenue increased by 34.82% due to business growth[9] - Net profit attributable to shareholders increased by 34.27% driven by business expansion[9] - Net profit attributable to shareholders after deducting non-recurring gains and losses rose by 66.65% as a result of business growth[9] Research and Development - Research and development expenses increased to CNY 12,289,064.34 in Q1 2022, compared to CNY 9,878,808.23 in Q1 2021, reflecting a growth of 24.3%[19] - Future outlook includes continued investment in R&D to drive innovation and market expansion strategies[19] Other Financial Metrics - The company reported a fair value loss of RMB 14,472,000 related to trading financial assets, impacting net profit[5] - The unrealized gain from biological assets was RMB 34,494,000, contributing positively to net profit[6] - The company received government subsidies amounting to RMB 2,580,000 during the reporting period[5] - The weighted average return on net assets decreased by 1.34 percentage points due to the full weighting of net assets raised from the Hong Kong stock issuance[9] - The company's total profit for Q1 2022 was CNY 139,756,935.47, up from CNY 104,035,964.94 in Q1 2021, reflecting an increase of 34.4%[20]
昭衍新药(06127) - 2021 - 年度财报
2022-04-28 10:13
Financial Performance - JOINN Laboratories reported a revenue of RMB 1.2 billion for the fiscal year 2021, representing a year-over-year growth of 25%[6]. - The company achieved a net profit of RMB 300 million, which is an increase of 30% compared to the previous year[6]. - Total revenue for 2021 reached RMB 1,516,680,000, a 40.9% increase from RMB 1,075,905,000 in 2020[14]. - Gross profit for 2021 was RMB 735,678,000, resulting in a gross margin of 48.51%[14]. - Net profit attributable to equity shareholders for 2021 was RMB 557,460,000, up from RMB 312,950,000 in 2020, reflecting an increase of 78.5%[14]. - Basic earnings per share for 2021 were RMB 1.51, compared to RMB 0.99 in 2020, representing a 52.5% increase[14]. - The company reported a gross margin of 45%, which is an improvement from 42% in the previous year[6]. - In 2021, the company achieved a revenue growth of approximately 41% year-on-year, with net profit attributable to equity shareholders increasing by about 78%[16]. - The company reported a profit distribution plan for the year ending December 31, 2021, proposing a final dividend of RMB 0.36 per share, up from RMB 0.35 in 2020[73]. - The total amount of the proposed final dividend is approximately RMB 137,248,000, compared to RMB 94,850,000 in 2020[73]. Market Expansion and Strategy - JOINN Laboratories plans to expand its market presence in Europe and North America, targeting a 20% increase in international revenue by 2023[6]. - The company plans to continue expanding its market presence and investing in new product development[12]. - The company aims to enhance its global footprint and service capabilities, leveraging the strategic acquisition of Biomere to upgrade facilities and expand services in the North American pharmaceutical market[48]. - The company is focusing on strategic partnerships with leading pharmaceutical companies to enhance its service offerings[6]. - The company plans to invest in expanding its clinical trial services and strengthen its scientific and regulatory teams to support clinical trial operations[48]. Research and Development - The company is investing RMB 200 million in R&D for new drug development technologies, aiming to launch two new products by the end of 2022[6]. - Research and development efforts are focused on innovative drug discovery and enhancing drug metabolism studies[11]. - The company has established a comprehensive platform for non-clinical evaluation, focusing on innovative drug research and evaluation capabilities across various new technologies and targets[19]. - The company successfully created gene-edited cell lines and animal models for rare disease drug development, enhancing its innovative drug research capabilities[22]. Operational Efficiency - JOINN Laboratories is implementing new operational strategies to improve efficiency, aiming for a 10% reduction in operational costs by 2023[6]. - The company upgraded its laboratory information management system (LIMS) and introduced new document management and employee training systems to enhance operational efficiency[19]. - The company expanded its workforce to over 2,100 professionals by December 31, 2021, enhancing the capabilities of its non-clinical research service team[17]. Acquisitions and Partnerships - JOINN Laboratories has completed the acquisition of Biomedical Research Models, Inc., enhancing its capabilities in preclinical research[6]. - The company is exploring potential mergers and acquisitions to strengthen its market position and capabilities[12]. - The company aims to selectively pursue acquisitions of businesses and assets that complement its growth strategy, particularly in non-clinical research and drug discovery services[52]. Financial Position and Assets - Total assets as of December 31, 2021, amounted to RMB 8,537,077,000, significantly higher than RMB 2,172,902,000 in 2017[15]. - Total liabilities for 2021 were RMB 1,392,641,000, compared to RMB 951,093,000 in 2020[15]. - Net assets for 2021 stood at RMB 7,144,436,000, an increase from RMB 1,221,809,000 in 2017[15]. - Cash and cash equivalents as of December 31, 2021, were RMB 41,541 million, an increase of 1,245.7% from RMB 3,087 million as of December 31, 2020[43]. Risks and Challenges - The company faces regulatory compliance risks due to the need to adhere to multiple laws and regulations across different countries, which could adversely affect its reputation and financial performance[53]. - Talent recruitment risks are heightened as the company expands, necessitating the cultivation and introduction of skilled personnel to meet current and future business needs[54]. - Market competition risks are increasing as competitors expand capacity and facilities, necessitating the company to maintain its core competitive advantages[55]. - The ongoing COVID-19 pandemic poses challenges to daily operations, and future developments in the pandemic could impact business operations depending on national policies[59]. Corporate Governance - The board consists of 10 members, with executive directors having service contracts established in February 2021 for an initial term of three years[83]. - The company has established a framework for maintaining shareholder interests and enhancing corporate value through effective governance practices[152]. - The board of directors held seven meetings during the reporting period, exceeding the minimum requirement of four meetings per year[175]. - The company has adopted a board nomination policy outlining criteria for selecting candidates for appointment or reappointment[166]. Shareholder Relations - The company emphasizes the importance of effective communication with shareholders to enhance investor relations[195]. - Shareholders holding more than 3% of the company's shares can propose temporary motions at least 10 days before the annual general meeting[193]. - The company has established a policy to maintain communication with shareholders, ensuring timely responses to shareholder concerns and suggestions[195]. Employee and Labor Relations - The company has established a union in China to represent employees and ensure compliance with labor laws and regulations[138]. - The employer matches employee contributions to the 401(k) plan up to 4% of eligible wages, providing a safety net for retirement savings[141]. Environmental and Social Responsibility - The company has established detailed internal rules for environmental protection, with no additional costs incurred for compliance as of December 31, 2021[74]. - The company emphasizes compliance with anti-bribery and anti-corruption regulations to mitigate risks associated with bribery and corruption[138]. - The company made donations amounting to RMB 1.2 million during the reporting period[151].